Vitamin-A treatment trial for Covid loss of smell
Volunteers will receive brain scans and be asked to sniff powerful odours such as rotten eggs and roses. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 28, 2021 Category: Consumer Health News Source Type: news
Vitamin A treatment trial for Covid loss of smell
Volunteers will receive brain scans and be asked to sniff powerful odours such as rotten eggs and roses. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 28, 2021 Category: Consumer Health News Source Type: news
Penn gene therapy spinout taking on rare retinal diseases launches with $19M in seed funding
A new gene therapy company attempting to commercialize the research of Penn Medicine's Dr. Jean Bennett launched Wednesday in North Carolina with $19 million in seed capital.
The company, Opus Genetics, is the first spinout company internally conceived and launched by the Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness. The fund was created to further the foundation's mission of backing research to prevent, treat and cure retin al degenerative diseases.
Opus… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 22, 2021 Category: American Health Authors: John George Source Type: news
Gene Therapy Research Accelerates for Retinal Diseases Gene Therapy Research Accelerates for Retinal Diseases
Patients who have rare retinal diseases — as well as those with more common ones — may benefit from a surge in gene therapy research.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
